Cutaneous melanoma: A model to study cancer metastasis

Journal of Surgical Oncology

Volumn 103, Issue 6, 2011, Pages 538-549

  Leong, Stanley P L ^a,i   Gershenwald, Jeffrey E ^b   Soong, Seng Jaw ^c   Schadendorf, Dirk ^d   Tarhini, Ahmad A ^e   Agarwala, Sanjiv ^f   Hauschild, Axel ^g   Soon, Christopher W M ^h   Daud, Adil ^h   Kashani Sabet, Mohammed ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f St Luke's Cancer Center   (United States)

^g UNIVERSITY OF KIEL   (Germany)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Sutter Pacific Medical Foundation   (United States)

Author keywords

melanoma; metastasis

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; AUTOANTIBODY; BCG VACCINE; CARBOPLATIN; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GSK 2118436; IPILIMUMAB; LACTATE DEHYDROGENASE; LEVODOPA; MELANOMA INHIBITING ACTIVITY PROTEIN; MELPHALAN; ONCOLYTIC HERPES VIRUS; PACLITAXEL; PEGINTERFERON ALPHA2B; PEPTIDE VACCINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLX 4032; PROTEIN S100B; SECRETORY PROTEIN; SORAFENIB; TEMOZOLOMIDE; TUMOR ASSOCIATED ANTIGEN 90 IMMUNE COMPLEX; TUMOR MARKER; TUMOR NECROSIS FACTOR; TYROSINE; UNCLASSIFIED DRUG; VELIMOGENE ALIPLASMID;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; DISTANT METASTASIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LIMB PERFUSION; LOW DRUG DOSE; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; OUTCOME ASSESSMENT; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; MELANOMA; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953897102     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21816     Document Type: Article

References (138)

1. Balch CM, Gershenwald JE, Soong SJ, et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206. Epub 2009 Nov 16.
2. Liu V, Mihm M,: Pathology of malignant melanoma. Surg Clin North Am 2003; 83: 31-60, v. (Pubitemid 36384359)
3. Allen P, Coit D,: The surgical management of metastatic melanoma. Ann Surg Oncol Oct 2002; 98: 762-770.
4. Debois J,: The anatomy and clinics of metastatic cancer. Norwell, MA: Kluwer Academic Publishers; 2002.
5. Akslen L, Heuch I, Hartveit F,: Metastatic patterns in autopsy cases of cutaneous melanoma. Invasion Metastasis 1988; 8: 193-204.
6. Patel J, Didolkar M, Pickren J, et al.: Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg Pathol 1978; 135: 807-810. (Pubitemid 8377329)
7. Essner R,: Surgical treatment of malignant melanoma. Surg Clin North Am 2003; 83: 109-156. (Pubitemid 36384363)
8. Paget S,: The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-573.
9. Fidler I,: The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458. (Pubitemid 37328849)
10. Morton D, Wen D, Wong J, et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
11. Morton DL, Thompson JF, Cochran AJ, et al.: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-1317. (Pubitemid 44465459)
12. Leong SP,: Sentinel lymph node mapping and selective lymphadenectomy: The standard of care for melanoma. Curr Treat Options Oncol 2004; 5: 185-194. (Pubitemid 39359619)
13. Leong SP,: Selective sentinel lymphadenectomy for malignant melanoma. Surg Clin North Am 2003; 83: 157-185, vii. (Pubitemid 36384364)
14. Hellman S,: Natural history of small breast cancer. J Clin Oncol 1994; 12: 2229-2234. (Pubitemid 24356043)
15. Leong SP,: Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol 2004; 11: 192S-197S.
16. Balch C,: Melanoma of the Skin. In:, Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual, 6th edition. New York: Springer Verlag; 2002.
17. Balch C, Buzaid A, Soong S, et al.: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648. (Pubitemid 32786276)
18. Balch CM, et al.: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634. (Pubitemid 32786275)
19. Balch C, Gershenwald J, Soong S, et al.: Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: Comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28: 2452-2459.
20. Gershenwald J, Soong S, Balch C,: TNM staging system for cutaneous melanoma and beyond. Ann Surg Oncol 2010; 17: 1475-1477.
21. Soong S, Ding S, Coit D, et al.: Predicting survival outcome of localized melanoma: An electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol 2010; 17: 2006-2014.
22. Soong S, Shaw H, Balch C, et al.: Predicting survival and recurrence in localized melanoma: A multivariate approach. World J Surg 1991; 16: 191-195.
23. Bowles T, Xing Y, Hu C, et al.: Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol 2010; 17: 2015-2023.
24. Xing Y, Chang G, Hu C, et al.: Conditional survival estimates improve over time for patients with advanced melanoma: Results from a population-based analysis. Cancer 2010; 116: 2234-2241.
25. Ding S, Soong S, Lin H, et al.: Parametric modeling of localized melanoma prognosis and outcome. J Biopharm Stat 2009; 19: 732-747.
26. Gogas H, Eggermont A, Hauschild A, et al.: Biomarkers in melanoma. Ann Oncol 2009; 20: vi8-13. Review.
27. Campora E, Repetto L, Giuntini P, et al.: LDH in the follow-up of stage I malignant melanoma. Eur J Cancer Clin Oncol 1988; 24: 277-278. (Pubitemid 18051199)
28. Agarwala S, Keilholz U, Gilles E, et al.: LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009; 45: 1807-1814.
29. Henze G, Dummer R, Joller-Jemelka H, et al.: Serum S100-A marker for disease monitoring in metastatic melanoma. Dermatology 1997; 194: 208-212. (Pubitemid 27216030)
30. Buer J, Probst M, Franzke A, et al.: Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 1997; 75: 1373-1376. (Pubitemid 27179831)
31. Hauschild A, Engel G, Brenner W, et al.: S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999; 56: 338-344. (Pubitemid 29240361)
32. Bogdahn U, Apfel R, Hahn M, et al.: Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 1989; 49: 5358-5363. (Pubitemid 19240474)
33. Apfel R, Lottspeich F, Hoppe J, et al.: Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma Res 1992; 2: 327-336. (Pubitemid 23084479)
34. Blesch A, Bosserhoff AK, Apfel R, et al.: Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 1994; 54: 5695-5701. (Pubitemid 24346269)
35. Bosserhoff A, Kaufmann M, Kaluza B, et al.: Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57: 3149-3153. (Pubitemid 27351728)
36. Garnier J, Letellier S, Cassinat B, et al.: Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 2007; 43: 816-821. (Pubitemid 46502913)
37. Faries M, Gupta R, Ye X, et al.: A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Invest 2007; 25: 285-293. (Pubitemid 47185072)
38. Schmidt H, Johansen J, Sjoegren P, et al.: Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 2006; 24: 798-804. (Pubitemid 46622047)
39. Ugurel S, Rappl G, Tilgen W, et al.: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-583. (Pubitemid 32112873)
40. Helfrich I, Edler L, Sucker A, et al.: Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009; 15: 1384-1392.
41. Utikal J, Schadendorf D, Ugurel S,: Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 2007; 298: 469-477. (Pubitemid 46295062)
42. Gogas H, Ioannovich J, Dafni U, et al.: Prognostic significance of autoimmunity during treatment of melanoma with interferon. NEJM 2006; 354: 709-718. (Pubitemid 43247141)
43. Bouwhuis M, Suciu S, Testori A, et al.: Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: Prognostic significance of autoantibodies-EORTC 18991. J Clin Oncol 2010; 28: 2460-2466.
44. Bouwhuis M, Suciu S, Collette S, et al.: EORTC Melanoma Group and the Nordic Melanoma Group. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009; 101: 869-877.
45. Mian S, Ugurel S, Parkinson E, et al.: Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 2005; 23: 5088-5093. (Pubitemid 46224016)
46. Findeisen P, Zapatka M, Peccerella T, et al.: Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 2009; 27: 2199-2208.
47. Clark WH, Jr., Elder D, Guerry D, IV, et al.: A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15: 1147-1165. (Pubitemid 15128121)
48. Davies H, Bignell G, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871)
49. Pollock P, Harper U, Hansen K, et al.: High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19-20. (Pubitemid 36068675)
50. Haqq C, Nosrati M, Sudilovsky D, et al.: The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 2005; 102: 6092-6097. (Pubitemid 40594260)
51. Kashani-Sabet M, Rangel J, Torabian S, et al.: A multi-marker assay to distinguish benign nevi from malignant melanomas. Proc Natl Acad Sci USA 2009; 106: 6268-6272.
52. Kashani-Sabet M, Venna S, Rangel J, et al.: A multi-marker prognostic assay for melanoma. Clin Cancer Res 2009; 15: 6987-6992.
53. Rangel J, Torabian S, Shaikh L, et al.: Prognostic significance of NCOA3 overexpression in primary cutaneous melanoma. J Clin Oncol 2006; 24: 4565-4569. (Pubitemid 46630952)
54. Rangel J, Nosrati M, Torabian S, et al.: Osteopontin as a molecular prognostic marker for melanoma. Cancer 2008; 112: 144-150.
55. Rangel J, Nosrati M, Leong S, et al.: Novel role for RGS1 in melanoma progression. Am J Surg Pathol 2008; 32: 1207-1212.
56. Clemente CG, et al.: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-1310. (Pubitemid 26102328)
57. Hakansson A, et al.: Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996; 74: 670-676. (Pubitemid 26300755)
58. Mihm MC, Jr., Clemente C, Cascinelli N,: Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74: 43-47. (Pubitemid 26041007)
59. Moschos SJ, et al.: Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24: 3164-3171. (Pubitemid 46638955)
60. Tatsumi T, et al.: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002; 196: 619-628. (Pubitemid 35024440)
61. Tatsumi T, et al.: Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003; 63: 4481-4489. (Pubitemid 36951020)
62. Kirkwood JM, et al.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17. (Pubitemid 26019991)
63. Kirkwood JM, et al.: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-2380. (Pubitemid 32391207)
64. Kirkwood JM, et al.: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-2458. (Pubitemid 30415832)
65. Kirkwood JM, et al.: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 1670-1677. (Pubitemid 38435557)
66. Kirkwood JM, et al.: High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001; 19: 1430-1436. (Pubitemid 32202550)
67. Wheatley K, Ives N, Hancock B, et al.: Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29: 241-252. (Pubitemid 37069655)
68. Wheatley K, Eggermont A, Kirkwood J,: Interferon-alfa as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. In ASCO Annual Meeting. 2007. Chicago.
69. Mocellin S, Pasquali S, Rossi CR, et al.: Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493-501.
70. Eggermont AM, et al.: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC18991, a randomised phase III trial. Lancet 2008; 372: 117-126. (Pubitemid 351952257)
71. Borgstein PJ, Meijer S, van Diest PJ,: Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 1999; 6: 315-321. (Pubitemid 29221020)
72. Ross MI, Reintgen D, Balch CM,: Selective lymphadenectomy: Emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993; 9: 219-223. (Pubitemid 23154458)
73. Cascinelli N, Bufalino R, Maroda R, et al.: Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986; 12: 175-180. (Pubitemid 16011038)
74. Wong JH, Cagle LA, Kopald KH, et al.: Natural history and selective management of in transit melanoma. J Surg Oncol 1990; 44: 146-150. (Pubitemid 20221427)
75. Leon P, Daly JM, Synnestredt M, et al.: The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991; 126: 1461-1468.
76. Day CL, Jr., Harrist TJ, Gorstein F, et al.: Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg 1981; 194: 108-112. (Pubitemid 12197159)
77. Creech O, Jr., Krementz ET, Ryan RF, et al.: Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-632.
78. Alexander HR, Fraker DL, Bartlett DL, et al.: Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 2010; 28: 114-118.
79. Senzer NN, Kaufman HL, Amatruda T, et al.: Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-5771.
80. Agarwala S, Thompson J, Smithers B, et al.: Chemoablation of metastatic melanoma with rose Bengal (PV10). J Clin Oncol 2010; 619s: Abstract 8534.
81. Campbell S, Khosravi-Far R, Rossman K, et al.: Increasing complexity of Ras signaling. Oncogene 1998; 17: 1395-1413. (Pubitemid 28458409)
82. Tsao H, Zhang X, Fowlkes K, et al.: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000; 60: 1800-1804. (Pubitemid 30207633)
83. Curtin J, Fridlyand J, Kageshita T, et al.: Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147. (Pubitemid 41653105)
84. Taube J, Begum S, Shi C, et al.: Benign nodal nevi frequently harbor the activating V600E BRAF mutation. Am J Surg Pathol 2009; 33: 568-571.
85. Goel V, Ibrahim N, Jiang G, et al.: Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 2009; 28: 2289-2298.
86. Dankort D, Curley D, Cartlidge R, et al.: BRafV600E cooperates with Pten loss to elicit metastatic melanoma. Nat Genet 2009; 41: 544-552.
87. Flaherty K, Puzanov I, Sosman J, et al.: Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer [abstract]. N Engi J Med 2010; 363: 809-819.
88. A study of RO5185426 in previously treated patients with metastatic melanoma. ClinicalTrials.gov. Available at: (accessed on June 26, 2010).
89. A study of RO5185426 in comparison with dacarbazine in previously untreated patients with metastatic melanoma. ClinicalTrials.gov. Available at: (accessed on June 26, 2010).
90. Kefford R, Arkenau H, Brown M, et al.: Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28: 8503.
91. Adjei A, Cohen R, Franklin W, et al.: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26: 2139-2146.
92. Study of XL184 in adults with advanced malignancies. ClinicalTrials.gov. Available at: (accessed on June 26, 2010).
93. Investigate safety, pharmacokinetics and pharmacodynamics of GSK2118436 & GSK1120212. ClinicalTrials.gov. Available at: (accessed on June 26, 2010).
94. Engelman J, Luo J, Cantley L,: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619. (Pubitemid 44100518)
95. Downward J,: PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15: 177-182. (Pubitemid 38251646)
96. Cantley L, Neel B,: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96: 4240-4245. (Pubitemid 29190320)
97. Dhawan P, Singh A, Ellis D, et al.: Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res 2002; 62: 7335-7342. (Pubitemid 36025257)
98. Guldberg P, thor Straten P, Birck A, et al.: Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997; 57: 3660-3663. (Pubitemid 27381203)
99. Reifenberger J, Wolter M, Boström J, et al.: Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch 2000; 436: 487-493. (Pubitemid 30312165)
100. Birck A, Ahrenkiel V, Zeuthen J, et al.: Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 2000; 114: 277-280. (Pubitemid 30417761)
101. Dai D, Martinka M, Li G,: Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J Clin Oncol 2005; 23: 1473-1482.
102. Dose-escalation study of GSK2126458. ClinicalTrials.gov. Available at: (accessed on June 26, 2010).
103. A study of GDC-0941 in patients with locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable. ClinicalTrials.gov. Available at: (accessed on June 26, 2010).
104. A dose escalation study of SF1126, a PI3 Kinase (PI3K) inhibitor, given by intravenous (IV) infusion in patients with solid tumors. ClinicalTrials.gov. Available at: (accessed on June 26, 2010).
105. Ibrahim N, Haluska F,: Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009; 4: 551-579.
106. Karbowniczek M, Spittle C, Morrison T, et al.: mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008; 128: 980-987. (Pubitemid 351374287)
107. Maira S, Stauffer F, Brueggen J, et al.: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-1863.
108. Chabot B, Stephenson D, Chapman V, et al.: The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988; 335: 88-89.
109. Geissler E, Ryan M, Housman D,: The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988; 55: 185-192.
110. Curtin J, Busam K, Pinkel D, et al.: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346. (Pubitemid 46630793)
111. Ugurel S, Hildenbrand R, Zimpfer A, et al.: Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005; 92: 1398-1405. (Pubitemid 40705006)
112. Wyman K, Atkins M, Prieto V, et al.: Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy. Cancer 2006; 106: 2005-2011. (Pubitemid 43673217)
113. Carvajal R, Chapman P, Wolchok J, et al.: A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT [abstract]. J Clin Oncol 2009; 27: Abstract 9001.
114. Minor D, O'Day S, Kashani-Sabet M, et al.: Sunitinib therapy for metastatic melanomas with KIT aberrations. J Clin Oncol 2010; 28: 8545.
115. Kalinsky K, Lee S, Lawrence D, et al.: A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607). J Clin Oncol 2010; 28: TPS312.
116. Yarden Y,: The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: S3-S8. (Pubitemid 32938123)
117. Sparrow L, Heenan P,: Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization. Australas J Dermatol 1999; 40: 19-24. (Pubitemid 29128086)
118. Ueno Y, Sakurai H, Tsunoda S, et al.: Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 2008; 123: 340-347. (Pubitemid 351842018)
119. Djerf E, Trinks C, Abdiu A, et al.: ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: Inhibition by gefitinib (ZD1839). Melanoma Res 2009; 19: 156-166.
120. Buac K, Xu M, Cronin JJ, et al.: NRG1/ERBB3 signaling in melanocyte development and melanoma: Inhibition of differentiation and promotion of proliferation. Pigment Cell Melanoma Res 2009; 22: 773-784.
121. Prickett T, Agrawal N, Wei X, et al.: Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009; 41: 1127-1132.
122. Gentile A, Trusolino L, Comoglio P,: The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008; 27: 85-94.
123. Hsu MY, Meier F, Herlyn M,: Melanoma development and progression: A conspiracy between tumor and host. Differentiation 2002; 70: 522-536. (Pubitemid 36194317)
124. Economou M, All-Ericsson C, Bykov V, et al.: Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: Intercorrelation and prognostic implications. Acta Ophthalmol 2008; 86: 20-25.
125. Bos JL,: Ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682-4689. (Pubitemid 19213607)
126. Adjei AA,: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062-1074. (Pubitemid 32717538)
127. Sharma A, et al.: Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005; 65: 2412-2421. (Pubitemid 40490153)
128. Hauschild A, et al.: Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2010; 27: 2823-2830.
129. Flaherty K, Lee S, Schuchter L, et al.: Final results of E2603: a double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. J Clin Oncol 2010; 28: 15S, Abstr 8511: 613s
130. Tsai J, Lee JT, Wang W, et al.: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105: 3041-3046. (Pubitemid 351723664)
131. Kefford R, Arkenau H, Brown M, et al.: Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF inase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28: 15S, Abstr 8503: 611s.
132. Patel S, Lazar A, Mahoney S, et al.: Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. J Clin Oncol 2010; 28: 15S, Abstr 8501: 611s
133. Bennett D,: How to make a melanoma: What do we know of the primary clonal events? Pigment Cell Melanoma Res 2008; 21: 27-238. Review.
134. Margolin K, et al. CCI-779 in metastatic melanoma: A phase II trialof the California Cancer Consortium. Cancer 2005; 104: 1045-1048. (Pubitemid 41170233)
135. Heinrich MC, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710. (Pubitemid 36159485)
136. Becker JC, et al. Imatinib in melanoma: A selective treatment option based on KIT mutation status? J Clin Oncol 2007. 25: e9. (Pubitemid 350002910)
137. Beadling C, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14: 6821-6828.
138. Hodi FS, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26: 2046-2051.